Published in Nat Immunol on October 28, 2007
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
The acute respiratory distress syndrome. J Clin Invest (2012) 5.61
The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol (2008) 3.35
Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest (2009) 2.41
Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res (2008) 1.85
Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell (2009) 1.79
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Signal transduction by protease-activated receptors. Br J Pharmacol (2010) 1.64
Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem (2010) 1.48
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med (2011) 1.28
Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood (2007) 1.26
Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv (2009) 1.24
Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care (2008) 1.22
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther (2008) 1.22
The G protein betagamma subunit mediates reannealing of adherens junctions to reverse endothelial permeability increase by thrombin. J Exp Med (2009) 1.21
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res (2010) 1.11
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost (2009) 1.10
Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost (2013) 1.10
Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem (2012) 1.10
Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol (2009) 1.07
Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal (2013) 1.06
Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci U S A (2011) 1.06
Activated protein C: biased for translation. Blood (2015) 1.05
Matrix metalloproteases and PAR1 activation. Blood (2012) 1.05
Role of G protein-coupled receptors in inflammation. Acta Pharmacol Sin (2012) 1.05
Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. J Biol Chem (2013) 1.03
Heterotrimeric G proteins, focal adhesion kinase, and endothelial barrier function. Microvasc Res (2011) 1.02
Influenza infects lung microvascular endothelium leading to microvascular leak: role of apoptosis and claudin-5. PLoS One (2012) 1.01
Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A (2013) 1.00
Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol (2009) 1.00
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol Biol (2011) 0.99
Mechanisms regulating endothelial permeability. Pulm Circ (2014) 0.99
Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne) (2014) 0.97
Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol (2011) 0.97
Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol (2011) 0.95
Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood (2010) 0.95
Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4. J Biol Chem (2012) 0.93
Cooperative signaling via transcription factors NF-κB and AP1/c-Fos mediates endothelial cell STIM1 expression and hyperpermeability in response to endotoxin. J Biol Chem (2014) 0.93
Cofactoring and dimerization of proteinase-activated receptors. Pharmacol Rev (2013) 0.92
Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care (2012) 0.92
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood (2011) 0.90
New paradigms in sepsis: from prevention to protection of failing microcirculation. J Thromb Haemost (2015) 0.89
Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells. J Biol Chem (2012) 0.88
The anti-oxidative, anti-inflammatory, and protective effect of S100A8 in endotoxemic mice. Mol Immunol (2012) 0.86
Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. Curr Opin Hematol (2008) 0.86
The down regulation of neutrophil oxidative metabolism by S100A8 and S100A9: implication of the protease-activated receptor-2. Mol Immunol (2011) 0.84
Interface between hemostasis and adaptive immunity. Curr Opin Immunol (2010) 0.84
Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets. PLoS One (2013) 0.83
Vascular and dendritic cell coagulation signaling in sepsis progression. J Thromb Haemost (2009) 0.83
Serine proteases, serine protease inhibitors, and protease-activated receptors: roles in synaptic function and behavior. Brain Res (2011) 0.82
Allosteric modulation of protease-activated receptor signaling. Mini Rev Med Chem (2012) 0.81
Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. Am J Physiol Lung Cell Mol Physiol (2014) 0.81
Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38. Am J Pathol (2011) 0.81
Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol (2012) 0.80
Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection. J Immunol (2015) 0.79
Differential signaling by protease-activated receptors: implications for therapeutic targeting. Int J Mol Sci (2014) 0.78
Neutrophil proteinase 3 acts on protease-activated receptor-2 to enhance vascular endothelial cell barrier function. Arterioscler Thromb Vasc Biol (2012) 0.78
Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. Blood (2014) 0.78
Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics. J Biol Chem (2015) 0.77
Transient early neurotrophin release and delayed inflammatory cytokine release by microglia in response to PAR-2 stimulation. J Neuroinflammation (2012) 0.77
Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis. J Cell Mol Med (2015) 0.77
We can do it together: PAR1/PAR2 heterodimer signaling in VSMCs. Arterioscler Thromb Vasc Biol (2011) 0.77
Signal protein-derived peptides as functional probes and regulators of intracellular signaling. J Amino Acids (2011) 0.77
Transient receptor potential channel 1 maintains adherens junction plasticity by suppressing sphingosine kinase 1 expression to induce endothelial hyperpermeability. FASEB J (2015) 0.76
Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics. Methods Mol Biol (2015) 0.76
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol (2016) 0.76
Protease-activated receptors in hemostasis. Blood (2016) 0.76
Integration of endothelial protease-activated receptor-1 inflammatory signaling by ubiquitin. Curr Opin Hematol (2016) 0.75
MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage. Cell Rep (2016) 0.75
Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin. J Biol Chem (2016) 0.75
Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice. Front Pharmacol (2017) 0.75
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
The acute respiratory distress syndrome. N Engl J Med (2000) 25.38
The pathophysiology and treatment of sepsis. N Engl J Med (2003) 21.67
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell (1991) 11.51
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A (1983) 7.55
Septic shock. Lancet (2005) 6.67
Pathogenetic mechanisms of septic shock. N Engl J Med (1993) 6.64
Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science (2002) 5.35
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
Ras and Rho GTPases: a family reunion. Cell (2000) 4.21
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell (2005) 3.92
Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood (2004) 3.58
Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem (2005) 3.54
Determination of GTP loading on Rho. Methods Enzymol (2000) 2.97
Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med (2002) 2.96
Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol (1995) 2.80
A role for thrombin receptor signaling in endothelial cells during embryonic development. Science (2001) 2.55
Evans blue dye as a marker of albumin clearance in cultured endothelial monolayer and isolated lung. J Appl Physiol (1985) (1992) 2.50
Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest (2003) 2.22
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci (2001) 2.06
The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem (1996) 2.05
Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells. J Biol Chem (1998) 2.02
Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther (1999) 2.01
Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A (2002) 2.00
Mechanisms of mortality in early and late sepsis. Infect Immun (2006) 1.88
Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem (2000) 1.77
Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calcium, and RhoA. Circ Res (1998) 1.74
Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry (1999) 1.73
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res (2004) 1.68
Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J Biol Chem (1994) 1.68
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation (2001) 1.67
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation (2006) 1.60
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost (2003) 1.55
Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med (2005) 1.53
Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost (1996) 1.53
Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry (2000) 1.48
Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol (2003) 1.36
Interactions between the innate immune and blood coagulation systems. Trends Immunol (2004) 1.36
Roles of protease-activated receptors in a mouse model of endotoxemia. Blood (2006) 1.32
The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. J Clin Invest (1996) 1.31
Protection against acute pancreatitis by activation of protease-activated receptor-2. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem (1999) 1.25
Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol (2003) 1.15
Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. Circ Res (2003) 1.13
Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci U S A (2000) 1.11
Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res (2006) 1.11
Protease-activated receptor-2 activating peptide SLIGRL inhibits bacterial lipopolysaccharide-induced recruitment of polymorphonuclear leukocytes into the airways of mice. Am J Respir Cell Mol Biol (2002) 1.05
Modulation of Rho GTPase activity in endothelial cells by selective proteinase-activated receptor (PAR) agonists. J Thromb Haemost (2003) 0.98
A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats. Biochem Pharmacol (2005) 0.96
Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: determination of prothrombin fragment 1 + 2 and other markers. Haemostasis (1992) 0.78
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. Clin Ther (2003) 0.78
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell (2005) 3.92
Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med (2002) 2.96
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Protease-activated receptors in cardiovascular diseases. Circulation (2006) 2.10
Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A (2002) 2.00
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol (2003) 1.95
Video game play, child diet, and physical activity behavior change a randomized clinical trial. Am J Prev Med (2011) 1.91
Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell (2009) 1.79
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation (2006) 1.60
Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation (2013) 1.58
Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol (2006) 1.57
Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med (2005) 1.53
The role of pancreatic ductal secretion in protection against acute pancreatitis in mice*. Crit Care Med (2014) 1.46
A mouse model of acute biliary pancreatitis induced by retrograde pancreatic duct infusion of Na-taurocholate. Gut (2007) 1.42
Is smoking cessation associated with worse comorbid substance use outcomes among homeless adults? Addiction (2014) 1.41
Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res (2009) 1.39
Protection against acute pancreatitis by activation of protease-activated receptor-2. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med (2011) 1.28
Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. J Biol Chem (2005) 1.27
Activation of the STAT pathway in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2004) 1.25
Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J (2006) 1.24
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther (2008) 1.22
Active commuting to school and association with physical activity and adiposity among US youth. J Phys Act Health (2011) 1.21
Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier. Infect Immun (2005) 1.17
MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun (2013) 1.16
Density and proximity of fast food restaurants and body mass index among African Americans. Am J Public Health (2013) 1.16
MyD88 deficiency results in tissue-specific changes in cytokine induction and inflammation in interleukin-18-independent mice infected with Borrelia burgdorferi. Infect Immun (2006) 1.16
The endocrinology of pregnancy and fetal loss in wild baboons. Horm Behav (2006) 1.16
Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol (2003) 1.15
Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis. J Biol Chem (2007) 1.14
Inhibition of the Src and Jak kinases protects against lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2005) 1.14
Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res (2010) 1.11
Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res (2006) 1.11
Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci U S A (2011) 1.11
G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008) 1.10
Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem (2012) 1.10
Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem (2003) 1.10
ADAMTS4 (aggrecanase-1) cleaves human brain versican V2 at Glu405-Gln406 to generate glial hyaluronate binding protein. Biochem J (2004) 1.08
Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res (2008) 1.08
Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.07
Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Virol (2006) 1.07
Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci U S A (2011) 1.06
Death among geladas (Theropithecus gelada): a broader perspective on mummified infants and primate thanatology. Am J Primatol (2010) 1.05
Adherence to latent tuberculosis infection therapy among latino immigrants. Public Health Nurs (2006) 1.05
Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost (2004) 1.05
Matrix metalloproteases and PAR1 activation. Blood (2012) 1.05
Ethnic Minority Children's Active Commuting to School and Association with Physical Activity and Pedestrian Safety Behaviors. J Appl Res Child (2010) 1.02
Advancing cessation research by integrating EMA and geospatial methodologies: associations between tobacco retail outlets and real-time smoking urges during a quit attempt. Nicotine Tob Res (2013) 1.01
Protease-activated receptor-2 exerts contrasting model-specific effects on acute experimental pancreatitis. J Biol Chem (2008) 1.01
Calcium dependence of proteinase-activated receptor 2 and cholecystokinin-mediated amylase secretion from pancreatic acini. Am J Physiol Gastrointest Liver Physiol (2005) 1.01
Cause-effect relationships between zymogen activation and other early events in secretagogue-induced acute pancreatitis. Am J Physiol Gastrointest Liver Physiol (2007) 1.00
Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res (2004) 0.99
Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J (2003) 0.99
Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol Biol (2011) 0.99
Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule. Nat Med (2004) 0.98
Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis. J Biol Chem (2011) 0.97
Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol (2011) 0.97
Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem (2012) 0.97
Co-localization hypothesis: a mechanism for the intrapancreatic activation of digestive enzymes during the early phases of acute pancreatitis. World J Gastroenterol (2006) 0.96
Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann N Y Acad Sci (2009) 0.96
Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol (2011) 0.95
Bile acids induce pancreatic acinar cell injury and pancreatitis by activating calcineurin. J Biol Chem (2012) 0.95
Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv (2011) 0.95
A novel protease-activated receptor-1 interactor, Bicaudal D1, regulates G protein signaling and internalization. J Biol Chem (2010) 0.95
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation (2012) 0.94